The British Pharmaceutical Company Astrazeneca filed an application for the emergency use of the new drug based on antibodies to the American Supervision Office for Emergency Development and Drug Administration, Guardian reports.
According to the results of clinical trials, developed by Astrazeneca The drug reduces the risk of developing the symptoms of COVID-19 by 77%.
As noted in the publication, while vaccines rely on the active immune system for the development of the arsenal of target antibodies and cells fighting with infections, a new drug is therapy with antibodies called AZD7442. It contains laboratory antibodies intended to remain in the body for months to restrain the virus in case of infection.
Astrazeneca declares that it can help protect people who may not be enough strong immune response to vaccines against COVID.
The use of AZD7442 in the United States can be a great victory for Astrazeneca, whose widely used vaccine against COVID has not yet been approved in the United States, the publication says.